ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. research hub

Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

This study is looking for new ways to treat advanced lung cancer, specifically a type called NSCLC. It's testing a new treatment combination that targets specific proteins in the cancer to see how well it works. This is for adult patients who have certain features in their cancer.